FDA approves Alnylam’s ultra-rare disease drug Oxlumo
pharmaphorum
NOVEMBER 24, 2020
The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. The disease is also difficult to diagnose and often takes around six years before doctors correctly identify it.
52 
Let's personalize your content